Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CNS10-NPC for Retinitis Pigmentosa
NCT04284293Phase 1Active, not recruiting
- Sponsor
- Cedars-Sinai Medical Center
- Start
- Jul 2021
- Primary completion
- Jul 2026
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of CNS10 in retinitis pigmentosa (RP) (3 arms), sponsored by Cedars-Sinai Medical Center. Primary endpoints: Incidence of Adverse Events and Serious Adverse Events at 12 months, Complete Blood Count at 12 months and 6 more. Started Jul 2021; status: active, not recruiting.
02
Drugs
CNS10
03
Conditions
retinitis pigmentosa (RP)
Beyond the preview
Go deeper on NCT04284293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04284293.